Phase II study of seliciclib in patients with previously treated advanced nasopharyngeal cancer.

Trial Profile

Phase II study of seliciclib in patients with previously treated advanced nasopharyngeal cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 May 2009

At a glance

  • Drugs Seliciclib (Primary)
  • Indications Nasopharyngeal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 29 May 2009 Safety results from 23 patients in the lead-in part of the study have been reported at ASCO 2009. The trial will now proceed into the second part of the study; reported in a Cyclacel media release.
    • 08 Nov 2007 Recruitment is expected to start by the end of 2007.
    • 08 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top